Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Table 3

Changes in calcitonin and CEA during treatment.

Patient		Level at baseline	Maximum reduction (%)	Level at study exit	Increase from baseline; till study exit (%)	Best response
1	CT (pmol/L)	73900	—	77700	105,1	SD
	CEA (µg/L)	246,5	—	353,3	143,3
2	CT (pmol/L)	245	—	280	114,3	SD
	CEA (µg/L)	354,3	—	2208,0	623,2
3	CT (pmol/L)	6750	—	29800	441,4	PD
	CEA (µg/L)	1477,0	—	2081,0	140,9
4	CT (pmol/L)	12716	30,3	8869		PD
	CEA (µg/L)	216,9	4,9	247,9	114,3
5	CT (pmol/L)	680	37,3	1148	168,8	SD
	CEA (µg/L)	117,1	—	164,4	140,4
6	CT (pmol/L)	58	56,9	89	153,4	SD
	CEA (µg/L)	70,7	35,5	86,7	122,6
7	CT (pmol/L)	2156	—	5239	243	SD
	CEA (µg/L)	91,1	10,1	166,7	183

CT: calcitonin and CEA: carcinoembryonic antigen level.
—: there was no reduction in CT or CEA compared to baseline and : there was no increase in CT compared to baseline; patient is still on everolimus treatment.